457 related articles for article (PubMed ID: 32588337)
1. The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.
Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
Patient; 2020 Oct; 13(5):583-597. PubMed ID: 32588337
[TBL] [Abstract][Full Text] [Related]
2. Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices.
Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
Patient; 2023 Sep; 16(5):457-471. PubMed ID: 37072663
[TBL] [Abstract][Full Text] [Related]
3. Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options.
Jonker MF; Donkers B; Goossens LMA; Hoefman RJ; Jabbarian LJ; de Bekker-Grob EW; Versteegh MM; Harty G; Wong SL
Med Decis Making; 2020 Feb; 40(2):198-211. PubMed ID: 32065023
[No Abstract] [Full Text] [Related]
4. Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis.
van Eijndhoven E; Brauer M; Kee R; MacEwan J; Mucha L; Wong SL; Durand A; Shafrin J
J Med Econ; 2020 May; 23(5):474-483. PubMed ID: 31903813
[No Abstract] [Full Text] [Related]
5. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
[TBL] [Abstract][Full Text] [Related]
6. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis.
Bottomley C; Lloyd A; Bennett G; Adlard N
J Med Econ; 2017 Aug; 20(8):863-870. PubMed ID: 28562125
[TBL] [Abstract][Full Text] [Related]
7. Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
Wilson L; Loucks A; Bui C; Gipson G; Zhong L; Schwartzburg A; Crabtree E; Goodin D; Waubant E; McCulloch C
J Neurol Sci; 2014 Sep; 344(1-2):80-7. PubMed ID: 25037284
[TBL] [Abstract][Full Text] [Related]
8. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
[TBL] [Abstract][Full Text] [Related]
9. Patient and neurologist preferences in the UK for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment.
Tencer T; Will O; Kumar J; Cambron-Mellott MJ; Mackie DS; Beusterien K
Curr Med Res Opin; 2021 Sep; 37(9):1589-1598. PubMed ID: 34129418
[TBL] [Abstract][Full Text] [Related]
10. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
11. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
[TBL] [Abstract][Full Text] [Related]
13. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity.
Juto A; Fink K; Al Nimer F; Piehl F
Mult Scler Relat Disord; 2020 Jan; 37():101468. PubMed ID: 31683231
[TBL] [Abstract][Full Text] [Related]
14. Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment.
Kumar J; Cambron-Mellott MJ; Tencer T; Will O; Mackie DS; Beusterien K
Patient Prefer Adherence; 2021; 15():1515-1527. PubMed ID: 34267507
[TBL] [Abstract][Full Text] [Related]
15. Patients' preferences and willingness-to-pay for disease-modifying therapies.
Frost N; Freeman J; Brixner D; Mort J; Clem J; Ngorsuraches S
Mult Scler Relat Disord; 2019 Oct; 35():55-60. PubMed ID: 31323483
[TBL] [Abstract][Full Text] [Related]
16. Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.
Hernandez L; O'Donnell M; Postma M
Pharmacoeconomics; 2018 Oct; 36(10):1223-1252. PubMed ID: 29971666
[TBL] [Abstract][Full Text] [Related]
17. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing women's preferences for subsequent management in the event of incomplete evacuation of the uterus after misoprostol treatment for miscarriage.
Hentzen JEKR; Verschoor MA; Lemmers M; Ankum WM; Mol BWJ; van Wely M
Hum Reprod; 2017 Aug; 32(8):1674-1683. PubMed ID: 28575402
[TBL] [Abstract][Full Text] [Related]
19. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.
Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Reder AT
Patient; 2016 Apr; 9(2):171-80. PubMed ID: 26259849
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
